Literature DB >> 24831211

Early identification of transthyretin-related hereditary cardiac amyloidosis.

Eloisa Arbustini1, Giampaolo Merlini2.   

Abstract

Entities:  

Keywords:  cardiac magnetic resonance imaging; echocardiography; skeletal scintigraphy; survival; transthyretin amyloidosis

Mesh：

Substances：

Year:  2014        PMID： 24831211     DOI： 10.1016/j.jcmg.2014.03.007

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN： 1876-7591


× No keyword cloud information.
  7 in total

Review 1.  2021 Advocacy Statements for the Role of 99mTc-Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis: A Report of the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.

Authors:  Yih-Hwen Huang; Yen-Hung Lin; Ruoh-Fang Yen; Charles Jia-Yin Hou; Shan-Ying Wang; Shih-Chuan Tsai; Kung-Chu Ho; Ming-Hsien Lin; Chin-Ho Tsao; Chih-Yung Chang; Jin-Long Huang; Mei-Fang Cheng; Yen-Wen Wu
Journal:  Acta Cardiol Sin       Date:  2021-05       Impact factor: 2.672

2.  Molecular imaging of misfolded protein pathology for early clues to involvement of the heart.

Authors:  Giampaolo Merlini; Jagat Narula; Eloisa Arbustini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

3.  Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.

Authors:  Eve Piekarski; Renata Chequer; Vincent Algalarrondo; Ludivine Eliahou; Besma Mahida; Jonathan Vigne; David Adams; Michel S Slama; Dominique Le Guludec; Francois Rouzet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-06       Impact factor: 9.236

Review 4.  Can Nuclear Imaging Techniques Predict Patient Outcome and Guide Medical Management in Hereditary Transthyretin Cardiac Amyloidosis?

Authors:  Vincent Algalarrondo; Eve Piekarski; Ludivine Eliahou; Dominique Le Guludec; Michel S Slama; François Rouzet
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

Review 5.  Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Florint Kroi; Nils Fischer; Ana Gezin; Mahmoud Hashim; Mark Hermannes Rozenbaum
Journal:  Cardiol Ther       Date:  2020-12-14

6.  Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.

Authors:  Julian D Gillmore; Mary M Reilly; Caroline J Coats; Rob Cooper; Helen Cox; Mark R E Coyne; Andrew J Green; Ruth McGowan; William E Moody; Philip N Hawkins
Journal:  Adv Ther       Date:  2022-04-13       Impact factor: 4.070

7.  Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.

Authors:  Mark H Rozenbaum; Andrea Garcia; Daniel Grima; Diana Tran; Rahul Bhambri; Michelle Stewart; Benjamin Li; Bart Heeg; Maarten Postma; Ahmad Masri
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.